HAE KYUNG KIM, GEERT J. BIESSELS, MINHEUI YU, JIHOON BAE, ARIM CHOI, MINYOUNG LEE
{"title":"920-P：钠-葡萄糖共转运体 2 抑制剂的使用与 2 型糖尿病患者罹患痴呆症和帕金森病的风险--一项纵向、全国性、基于人群的队列研究","authors":"HAE KYUNG KIM, GEERT J. BIESSELS, MINHEUI YU, JIHOON BAE, ARIM CHOI, MINYOUNG LEE","doi":"10.2337/db24-920-p","DOIUrl":null,"url":null,"abstract":"The efficacy of sodium-glucose cotransporter 2 inhibitor (SGLT2i) in neurologic disorders is not well-established. This study aimed to investigate the association of SGLT2i use with risks of incident dementia and Parkinson’s disease (PD) in patient with type 2 diabetes. Subjects aged ≥ 40 years, diagnosed with type 2 diabetes, and who started antidiabetic drugs from 1 September 2014 and 31 December 2019 were evaluated, using the National Health Insurance Service Database. Propensity score matching (1:1; SGLT2i to other oral antidiabetic drugs [OAD]) produced a cohort of 358,862. Primary outcomes were a composite of dementia from any cause (Alzheimer’s disease [AD], vascular dementia [VaD], and other dementia) and PD. From the 358,862 participants analyzed (mean age, 57.8 years; 57.9% male), 6,837 incident dementia or PD events occurred. Overall, use of SGLT2i was associated with a 22% lower risk for the composite of dementia from any cause and PD than use of other OADs (adjusted HR [aHR], 0.78 [95% CI 0.73─0.83]) with a 6-month lag period. Regarding the individual endpoints, SGLT2i use was associated with reduced risks for AD (aHR, 0.81 [95% CI 0.76─0.87]), VaD (aHR, 0.69 [95% CI 0.60─0.78]), and PD (aHR, 0.80 [95% CI 0.69─0.91]). In this nationwide population-based cohort study, SGLT2i use significantly reduced the risks for dementia and PD in patients with type 2 diabetes independent of various factors including comorbidities and bioclinical parameters. Disclosure H. Kim: None. G.J. Biessels: None. M. Yu: None. J. Bae: None. A. Choi: None. M. Lee: Other Relationship; JW Pharmaceutical Corporation, Boryung Corporation, Eli Lilly and Company, Merck Sharp & Dohme Corp., HK inno.N, Servier Korea, Handok Inc., Daewoong Pharmaceutical, KUKJE PHARM CO., LTD, GC Biopharma Corporation. Funding Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HR22C141104)2); 'SENTINEL (Severance Endocrinology daTa scIeNcE pLatform)’ program funded by the 2020 Research fund of Department of Internal Medicine, Severance Hospital; Sung-Kil Lim Research Award (4-2018-1215; DUCD000002); Yonsei University College of Medicine (6-2020-0155)","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":null,"pages":null},"PeriodicalIF":6.2000,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"920-P: Sodium–Glucose Cotransporter 2 Inhibitor Use and Risk of Dementia and Parkinson’s disease among Patients with Type 2 Diabetes—A Longitudinal, Nationwide, Population-Based Cohort Study\",\"authors\":\"HAE KYUNG KIM, GEERT J. BIESSELS, MINHEUI YU, JIHOON BAE, ARIM CHOI, MINYOUNG LEE\",\"doi\":\"10.2337/db24-920-p\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The efficacy of sodium-glucose cotransporter 2 inhibitor (SGLT2i) in neurologic disorders is not well-established. This study aimed to investigate the association of SGLT2i use with risks of incident dementia and Parkinson’s disease (PD) in patient with type 2 diabetes. Subjects aged ≥ 40 years, diagnosed with type 2 diabetes, and who started antidiabetic drugs from 1 September 2014 and 31 December 2019 were evaluated, using the National Health Insurance Service Database. Propensity score matching (1:1; SGLT2i to other oral antidiabetic drugs [OAD]) produced a cohort of 358,862. Primary outcomes were a composite of dementia from any cause (Alzheimer’s disease [AD], vascular dementia [VaD], and other dementia) and PD. From the 358,862 participants analyzed (mean age, 57.8 years; 57.9% male), 6,837 incident dementia or PD events occurred. Overall, use of SGLT2i was associated with a 22% lower risk for the composite of dementia from any cause and PD than use of other OADs (adjusted HR [aHR], 0.78 [95% CI 0.73─0.83]) with a 6-month lag period. Regarding the individual endpoints, SGLT2i use was associated with reduced risks for AD (aHR, 0.81 [95% CI 0.76─0.87]), VaD (aHR, 0.69 [95% CI 0.60─0.78]), and PD (aHR, 0.80 [95% CI 0.69─0.91]). In this nationwide population-based cohort study, SGLT2i use significantly reduced the risks for dementia and PD in patients with type 2 diabetes independent of various factors including comorbidities and bioclinical parameters. Disclosure H. Kim: None. G.J. Biessels: None. M. Yu: None. J. Bae: None. A. Choi: None. M. Lee: Other Relationship; JW Pharmaceutical Corporation, Boryung Corporation, Eli Lilly and Company, Merck Sharp & Dohme Corp., HK inno.N, Servier Korea, Handok Inc., Daewoong Pharmaceutical, KUKJE PHARM CO., LTD, GC Biopharma Corporation. Funding Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HR22C141104)2); 'SENTINEL (Severance Endocrinology daTa scIeNcE pLatform)’ program funded by the 2020 Research fund of Department of Internal Medicine, Severance Hospital; Sung-Kil Lim Research Award (4-2018-1215; DUCD000002); Yonsei University College of Medicine (6-2020-0155)\",\"PeriodicalId\":11376,\"journal\":{\"name\":\"Diabetes\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.2000,\"publicationDate\":\"2024-06-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2337/db24-920-p\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2337/db24-920-p","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
920-P: Sodium–Glucose Cotransporter 2 Inhibitor Use and Risk of Dementia and Parkinson’s disease among Patients with Type 2 Diabetes—A Longitudinal, Nationwide, Population-Based Cohort Study
The efficacy of sodium-glucose cotransporter 2 inhibitor (SGLT2i) in neurologic disorders is not well-established. This study aimed to investigate the association of SGLT2i use with risks of incident dementia and Parkinson’s disease (PD) in patient with type 2 diabetes. Subjects aged ≥ 40 years, diagnosed with type 2 diabetes, and who started antidiabetic drugs from 1 September 2014 and 31 December 2019 were evaluated, using the National Health Insurance Service Database. Propensity score matching (1:1; SGLT2i to other oral antidiabetic drugs [OAD]) produced a cohort of 358,862. Primary outcomes were a composite of dementia from any cause (Alzheimer’s disease [AD], vascular dementia [VaD], and other dementia) and PD. From the 358,862 participants analyzed (mean age, 57.8 years; 57.9% male), 6,837 incident dementia or PD events occurred. Overall, use of SGLT2i was associated with a 22% lower risk for the composite of dementia from any cause and PD than use of other OADs (adjusted HR [aHR], 0.78 [95% CI 0.73─0.83]) with a 6-month lag period. Regarding the individual endpoints, SGLT2i use was associated with reduced risks for AD (aHR, 0.81 [95% CI 0.76─0.87]), VaD (aHR, 0.69 [95% CI 0.60─0.78]), and PD (aHR, 0.80 [95% CI 0.69─0.91]). In this nationwide population-based cohort study, SGLT2i use significantly reduced the risks for dementia and PD in patients with type 2 diabetes independent of various factors including comorbidities and bioclinical parameters. Disclosure H. Kim: None. G.J. Biessels: None. M. Yu: None. J. Bae: None. A. Choi: None. M. Lee: Other Relationship; JW Pharmaceutical Corporation, Boryung Corporation, Eli Lilly and Company, Merck Sharp & Dohme Corp., HK inno.N, Servier Korea, Handok Inc., Daewoong Pharmaceutical, KUKJE PHARM CO., LTD, GC Biopharma Corporation. Funding Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HR22C141104)2); 'SENTINEL (Severance Endocrinology daTa scIeNcE pLatform)’ program funded by the 2020 Research fund of Department of Internal Medicine, Severance Hospital; Sung-Kil Lim Research Award (4-2018-1215; DUCD000002); Yonsei University College of Medicine (6-2020-0155)
期刊介绍：
Diabetes is a scientific journal that publishes original research exploring the physiological and pathophysiological aspects of diabetes mellitus. We encourage submissions of manuscripts pertaining to laboratory, animal, or human research, covering a wide range of topics. Our primary focus is on investigative reports investigating various aspects such as the development and progression of diabetes, along with its associated complications. We also welcome studies delving into normal and pathological pancreatic islet function and intermediary metabolism, as well as exploring the mechanisms of drug and hormone action from a pharmacological perspective. Additionally, we encourage submissions that delve into the biochemical and molecular aspects of both normal and abnormal biological processes.
However, it is important to note that we do not publish studies relating to diabetes education or the application of accepted therapeutic and diagnostic approaches to patients with diabetes mellitus. Our aim is to provide a platform for research that contributes to advancing our understanding of the underlying mechanisms and processes of diabetes.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
